Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Analysis of change in circulating microRNAs in mice during breast tumor development

ABSTRACT: The aim of this study was to analyse alterations in circulating microRNA expression during breast tumour progression in a murine model, and to apply significantly altered miRNAs to patient samples to identify novel circulating microRNA markers or tumour progression. Athymic nude mice (n=10) received an injection of 2 x 105 MDA-MB-231 cells. Tumour volume was monitored weekly and blood sampling performed at weeks 1 and 6 following tumour induction. A microRNA array was performed comparing circulating 384 microRNAs in animals with early (week 1, n=5) versus late (week 6, n=5) disease.

ORGANISM(S): Mus musculus Homo sapiens

PROVIDER: GSE47455 | GEO | 2013/09/01

SECONDARY ACCESSION(S): PRJNA205636

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Analysis of change in circulating microRNAs in mice during breast tumor development

Project description:The aim of this study was to analyse alterations in circulating microRNA expression during breast tumour progression in a murine model, and to apply significantly altered miRNAs to patient samples to identify novel circulating microRNA markers or tumour progression. Athymic nude mice (n=10) received an injection of 2 x 105 MDA-MB-231 cells. Tumour volume was monitored weekly and blood sampling performed at weeks 1 and 6 following tumour induction. A microRNA array was performed comparing circulating 384 microRNAs in animals with early (week 1, n=5) versus late (week 6, n=5) disease. Five animals were included in the study (n=2 samples from each, total n=10 microArrays performed), with whole blood sampled one week following tumor induction and again at 6 weeks in the presence of established disease. The change in microRNA profile was then compared at week 1 and week 6, which the "early" sample providing the baseline measurements for each animal.

2013-09-01 | E-GEOD-47455 | biostudies-arrayexpress

BevR-IgG array in glioblastoma xenografts

Project description:Analysis of anti-angiogenic therapy resistance in xenografts of patient glioma samples serially passaged across generations of athymic nude mice

2016-06-21 | GSE81465 | GEO

GSK3B shRNA in Panc-1 xenografts

Project description:The Panc-1 human pancreatic cancer line (ATCC) was constructed to stably express control or GSK3B shRNA. Control or GSK3B shRNA expressing Panc-1 cells were implanted subcutaneously into the flanks of 3-5 week old, female, athymic nude mice. Tumors were grown to at least 250mm3. Tumor tissue was microdissected for further analysis. We compared control shRNA (n=4) to GSK3B shRNA (n=3) Panc-1 xenografts. The array data with simple statistical calculations are also provided in a supplementary Excel workbook, with probe-set annotation that we used at the time (users may want newer annotation). We compared xenografts of Panc-1 (Human pancreatic carcinoma cell line, grown in mice) stably expressing GSK3B shRNA (n=3) to similar xenografts with control shRNA (n=4). Xenografts were grown in the flanks of female, athymic nude mice until they reached at least 250mm3. Tumor tissue was microdissected for further analysis. mRNA abundance assays were performed using Affymetrix HG_U133_plus_2 arrays, with 54675 probe-sets.

2014-01-09 | E-GEOD-35351 | biostudies-arrayexpress

Pharmacological inhibition of 17β-hydroxysteroid dehydrogenase inhibits endometrial cancer growth in an orthotopic xenograft mouse model

Project description:Experimental design: Endometrial tumours were induced orthotopically (in one uterine horn) in 8-week-old female athymic nude mice (Crl:NU(NCr)-Foxn1nu), using an Ishikawa-derived cell line (clones Ishi-M3-HSDA, described in Konings et al 2018). This cell line maintains the characteristics of the parental line (i.e., gives rise to well differentiated-estrogen sensitive adenocarcinomas) and further bears the luciferase gene for in vivo measurement of tumour growth by bioluminescence and expresses the enzyme 17β-hydroxysteroid dehydrogenase (HSD17B1). After tumour engraftment (approximately two weeks), baseline was defined, mice were ovariectomised (to remove the natural source of estrogens) and estrone was supplemented via subcutaneous pellets at a dose of 0.02 g/day. Mice were further assigned to one arm, receiving only estrone, and a second arm, receiving estrone plus the HSD17B1 inhibitor FP4643 at a dose of 25mg/Kg. At humane endpoint (approximately 10 weeks), mice were sacrificed, primary tumours were excised and snap-frozen. Tumours were divided on their largest diameter plane and slices for RNA isolation were prepared from such largest surface area of the primary tumours. Histology on mirror slices confirmed the present of tumour tissue and the absence of necrosis, inflammation and mouse endometrium.

2021-04-09 | E-MTAB-10338 | biostudies-arrayexpress

Transcription profiling of human in vivo xenograft models of estrogen receptor-positive (ER+) breast cancer, with or without HER2 over-expression (MCF7/HER2-18 and MCF7 wt, respectively)

Project description:To investigate molecular mechanisms of resistance, we used two different in vivo xenograft models of estrogen receptor-positive (ER+) breast cancer, with or without HER2 over-expression (MCF7/HER2-18 and MCF7 wt, respectively). Mice with established tumors were assigned to the following treatment groups: continued estrogen supplementation (E2), estrogen deprivation (ED), ED plus tamoxifen (Tam), all with or without the EGFR tyrosine kinase inhibitor gefinitinib (G). Another group received ED plus the antiestrogen fulvestrant (MCF7 wt only). Tumors with acquired or de novo resistance to these endocrine therapies were profiled for mRNA expression using Affymetrix Genechip arrays. Experiment Overall Design: MCF7 xenografts were established in ovariectomized five to six week-old nu/nu athymic nude mice supplemented with 0.25 mg 21 day release estrogen pellets by inoculating subcutaneously (s.c.) 5E-6 cells. When tumors reached the size of 150-200 mm3 (3-5 weeks), the animals were randomly allocated to continued estrogen (E2), continued estrogen with gefitinib (E2+G; 100mg/kg, 5 days/week), estrogen withdrawal alone (ED; by removal of the estrogen pellets), and estrogen withdrawal plus tamoxifen citrate (Tam; 500 microg/animal s.c. in peanut oil, 5 days/week), with either gefitinib (Tam+G; 100mg/kg, 5 days/week) or vehicle (1% Tween 80) administered via gavage, as well as estrogen withdrawal plus fulvestrant (ICI 182,780) in the MCF7 wt model (Fulv; 5mg/mouse s.c. once weekly), and estrogen withdrawal with gefitinib (ED+G). Tumors were harvested for molecular studies when they became resistant to treatment and reached the size of 1000 mm3 (n=7).

2009-01-13 | E-GEOD-8139 | biostudies-arrayexpress

Transcription profiling of mouse MCF7 wt xenografts

2009-01-13 | E-GEOD-8140 | biostudies-arrayexpress

Identification of an NKX3.1-G9a-UTY regulatory network that controls prostate differentiation (Mouse_Recomb_RNA-Seq)

Project description:Analysis of transcriptome of tissue recombinants (mouse seminal vesicle epithelial [SVE] cells or prostate epithelial [PE] cells, and rat urogenital sinus [UGS] mesenchymal cells) grown under the kidney capsule in athymic nude mice for 3 months.

2016-06-24 | GSE81432 | GEO

GSK3B shRNA in Panc-1 xenografts

2014-01-09 | GSE35351 | GEO

Transcription profiling of nude mice tumor biopsies generated by the injection of mesenchymal stem cells (MSC)

Project description:Transformed MSC were injected subcutaneously into the flank of athymic CD1 nude mice (C/River). Biopsies of 1.5 cm spindle cell tumours were taken.

2006-12-26 | E-MEXP-562 | biostudies-arrayexpress

Transcriptomic analysis of the host circulating leukocyte response to infestation with the ectoparasitic mite Psoroptes ovis

Project description:Sheep (N=6) infested with Psoroptes ovis mites were bled weekly and circulating leukocytes isolated from their whole blood samples. RNA was extracted and processed onto Agilent Bovine Microarrays and differentially expressed genes identified between the following time points (0 (Baseline (pre-infestation)), 1 week, 3 weeks and 6 weeks post-infestation).

2012-04-01 | E-TABM-1193 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data